Business
Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin
About this update from Protagonist Therapeutics, Inc.
[{"type":"text","content":"Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pillPN-881, a first-in-class oral peptide targeting the IL-17 pathway, potently and selectively binds IL-17A and -17F, blocking the three dimeric forms of the cytokine NEWARK, CA / ACCESS Newswire / May 9, 2025 / Protagonist Therapeutics, Inc. (\"Protagonist\" or the \"Company\") announced new clinical data from the Phase 3 ICONIC-TOTAL a study investigating icotrokinra, the first-in-class oral peptide antagonist targeting IL-23 receptor and preclinical characterization of PN-881, the first-in-class oral peptide antagonist blocking the three dimeric forms of IL-17 (AA, AF and FF), were presented separately today at the 2025 Society for Investigative Dermatology (SID) Annual Meeting in San Diego, CA.The ICONIC-TOTAL study, conducted by Protagonist's collaboration partner, Johnson & Johnson, evaluated adults and adolescents 12 years of age and older with body surface area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites.Key findings from the high-impact skin sites cohort of the icotrokinra ICONIC-TOTAL study [1] :At week 16, 57% of patients treated with once daily icotrokinra achieved the study's primary endpoint with an Investigator's Global Assessment (IGA) b score of 0/1 (clear or almost clear skin) and a ≥2-grade improvement from baseline at Week 16 compared to 6% of patients receiving placebo (P","length":2084,"tagName":"div"}]